These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10696255)

  • 21. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group.
    Nseyo UO; Shumaker B; Klein EA; Sutherland K
    J Urol; 1998 Jul; 160(1):39-44. PubMed ID: 9628601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescence diagnosis of bladder cancer.
    Chatterton K; Ray E; O'Brien TS
    Br J Nurs; 2006 Jun 8-21; 15(11):595-7. PubMed ID: 16835527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
    Mulders PF; Meyden AP; Doesburg WH; Oosterhof GO; Debruyne FM
    Br J Urol; 1994 Apr; 73(4):403-8. PubMed ID: 8199828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 25. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?
    Pagano F; Bassi P; Milani C; Meneghini A; Maruzzi D; Garbeglio A
    J Urol; 1991 Jul; 146(1):32-5. PubMed ID: 2056600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent or aggressive bladder cancer. Indications for adjuvant intravesical therapy.
    Badalament RA; Ortolano V; Burgers JK
    Urol Clin North Am; 1992 Aug; 19(3):485-98. PubMed ID: 1636233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Oettgen HF; Melamed MR
    Cancer; 1983 Apr; 51(7):1323-6. PubMed ID: 6337700
    [No Abstract]   [Full Text] [Related]  

  • 28. BCG in the management of superficial bladder cancer.
    Guinan P; Richardson C; Hanna M; Rubenstein M
    Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of superficial bladder tumours.
    Tung KH; Tan EC; Lam HS; Low CO; Foo KT; Tock EP
    Singapore Med J; 1987 Aug; 28(4):304-7. PubMed ID: 3423795
    [No Abstract]   [Full Text] [Related]  

  • 30. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):1027-38. PubMed ID: 12894724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intravesical bacillus Calmette-Guérin therapy for superficial bladder tumors].
    Hirano A; Shinka T; Uekado Y; Komura T; Kyoku I; Ohkawa T
    Nihon Hinyokika Gakkai Zasshi; 1987 Oct; 78(10):1769-75. PubMed ID: 3444170
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravesical therapy of bladder cancer: an immunotherapy success story.
    Morales A
    Int J Urol; 1996 Sep; 3(5):329-33. PubMed ID: 8886906
    [No Abstract]   [Full Text] [Related]  

  • 33. [Intravesical BCG therapy in patients with recurrent superficial bladder tumors].
    Sugimoto M; Yamamoto H; Itakura H; Shinohara M; Kinoshita K
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3725-8. PubMed ID: 2596855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superficial bladder cancer: state of the art.
    Bono AV
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S101-9. PubMed ID: 7994780
    [No Abstract]   [Full Text] [Related]  

  • 38. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management.
    Herr HW; Whitmore WF
    J Urol; 1987 Aug; 138(2):292-4. PubMed ID: 3599241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lower toxicity with the topical low-dose BCG therapy of superficial bladder carcinoma?].
    Mack D; Frick J
    Urologe A; 1992 Mar; 31(2):88-90. PubMed ID: 1561732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.
    Torti FM; Shortliffe LD; Williams RD; Pitts WC; Kempson RL; Ross JC; Palmer J; Meyers F; Ferrari M; Hannigan J
    J Clin Oncol; 1988 Mar; 6(3):476-83. PubMed ID: 3280742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.